Invention Grant
- Patent Title: Precision activation of HIV-specific CTLS to eliminate reactivated latent T cells
-
Application No.: US16603306Application Date: 2018-04-02
-
Publication No.: US11407806B2Publication Date: 2022-08-09
- Inventor: Harris Goldstein , Steven C. Almo
- Applicant: Albert Einstein College of Medicine
- Applicant Address: US NY Bronx
- Assignee: Albert Einstein College of Medicine
- Current Assignee: Albert Einstein College of Medicine
- Current Assignee Address: US NY Bronx
- Agency: Fox Rothschild LLP
- International Application: PCT/US2018/025621 WO 20180402
- International Announcement: WO2018/187190 WO 20181011
- Main IPC: A61P31/18
- IPC: A61P31/18 ; C07K14/045 ; C07K14/52 ; C12N15/62 ; A61K38/00 ; C07K14/74 ; C07K7/00
Abstract:
Compositions and methods to increase the in vivo capacity of CD8+ T cells to kill HIV-infected and reactivated latent HIV-infected T cells (LHITC) to functionally cure HIV infection or improve the clinical course. Compositions and methods to increase the in vivo capacity of CD8+ T cells to kill CMV or CMV-infected cells are also provided.
Public/Granted literature
- US20210107967A1 PRECISION ACTIVATION OF HIV-SPECIFIC CTLS TO ELIMINATE REACTIVATED LATENT T CELLS Public/Granted day:2021-04-15
Information query
